ES2332132T3 - Derivados de 2-(diaza-biciclo-alquil)-pirimidona sustituidos. - Google Patents

Derivados de 2-(diaza-biciclo-alquil)-pirimidona sustituidos. Download PDF

Info

Publication number
ES2332132T3
ES2332132T3 ES04717644T ES04717644T ES2332132T3 ES 2332132 T3 ES2332132 T3 ES 2332132T3 ES 04717644 T ES04717644 T ES 04717644T ES 04717644 T ES04717644 T ES 04717644T ES 2332132 T3 ES2332132 T3 ES 2332132T3
Authority
ES
Spain
Prior art keywords
group
diaza
methyl
bicyclo
hept
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04717644T
Other languages
English (en)
Spanish (es)
Inventor
Alistair Lochead
Mourad Saady
Franck Slowinski
Philippe Yaiche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Tanabe Pharma Corp
Original Assignee
Sanofi Aventis France
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03290570A external-priority patent/EP1454910A1/en
Priority claimed from EP20030290571 external-priority patent/EP1454908B1/en
Application filed by Sanofi Aventis France, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of ES2332132T3 publication Critical patent/ES2332132T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES04717644T 2003-03-07 2004-03-05 Derivados de 2-(diaza-biciclo-alquil)-pirimidona sustituidos. Expired - Lifetime ES2332132T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03290570 2003-03-07
EP03290570A EP1454910A1 (en) 2003-03-07 2003-03-07 Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP20030290571 EP1454908B1 (en) 2003-03-07 2003-03-07 Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
EP03290571 2003-03-07

Publications (1)

Publication Number Publication Date
ES2332132T3 true ES2332132T3 (es) 2010-01-27

Family

ID=32963795

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04717644T Expired - Lifetime ES2332132T3 (es) 2003-03-07 2004-03-05 Derivados de 2-(diaza-biciclo-alquil)-pirimidona sustituidos.

Country Status (22)

Country Link
US (2) US7211581B2 (https=)
EP (1) EP1603910B1 (https=)
JP (1) JP4778890B2 (https=)
KR (1) KR101072159B1 (https=)
AR (1) AR043486A1 (https=)
AT (1) ATE440844T1 (https=)
AU (1) AU2004218249B2 (https=)
BR (1) BRPI0408186A (https=)
CA (1) CA2516934C (https=)
CY (1) CY1111132T1 (https=)
DE (1) DE602004022784D1 (https=)
DK (1) DK1603910T3 (https=)
EA (1) EA008595B1 (https=)
ES (1) ES2332132T3 (https=)
IL (1) IL170468A (https=)
MX (1) MXPA05009575A (https=)
NO (1) NO20054141L (https=)
NZ (1) NZ542136A (https=)
PL (1) PL1603910T3 (https=)
PT (1) PT1603910E (https=)
SI (1) SI1603910T1 (https=)
WO (1) WO2004078759A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
EP1992620A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992621A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP1992625A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994460A (en) * 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
AU2001262150A1 (en) * 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136483A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
DE60302221T2 (de) * 2002-02-28 2006-08-03 Sanofi-Aventis Heteroaryl substituierte 2-pyridinyl und 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-onderivate

Also Published As

Publication number Publication date
NO20054141D0 (no) 2005-09-06
WO2004078759A1 (en) 2004-09-16
KR20050113218A (ko) 2005-12-01
SI1603910T1 (sl) 2009-12-31
AU2004218249B2 (en) 2009-04-30
JP4778890B2 (ja) 2011-09-21
US20070167455A1 (en) 2007-07-19
DE602004022784D1 (de) 2009-10-08
EA200501243A1 (ru) 2006-04-28
US7211581B2 (en) 2007-05-01
AR043486A1 (es) 2005-08-03
CA2516934C (en) 2011-09-20
JP2006519813A (ja) 2006-08-31
NZ542136A (en) 2008-07-31
EP1603910A1 (en) 2005-12-14
DK1603910T3 (da) 2009-11-23
PT1603910E (pt) 2009-10-30
NO20054141L (no) 2005-12-07
MXPA05009575A (es) 2006-05-19
ATE440844T1 (de) 2009-09-15
EA008595B1 (ru) 2007-06-29
HK1085742A1 (zh) 2006-09-01
AU2004218249A1 (en) 2004-09-16
IL170468A (en) 2010-12-30
EP1603910B1 (en) 2009-08-26
CY1111132T1 (el) 2015-06-11
US20060025417A1 (en) 2006-02-02
US7452897B2 (en) 2008-11-18
PL1603910T3 (pl) 2010-02-26
CA2516934A1 (en) 2004-09-16
BRPI0408186A (pt) 2006-04-04
KR101072159B1 (ko) 2011-10-10

Similar Documents

Publication Publication Date Title
ES2346311T3 (es) Derivados de 8-piridinil-dihidroespiro-cicloalquil-pirimido 1,2-a pirimidin-6-ona y 8-pirimidinil-dihidroespiro-cicloalquil-pirimido 1,2-a pirimidin-6-ona sustituidos y su uso contra enfermedades neurodegenerativas.
ES2286707T3 (es) Derivados de 8'-piri(mi)dinil-dihidrospiro-(cicloalquilimina)-pirimido(1,2-a)pirimidin-6-ona sustituidos.
ES2338325T3 (es) Derivados de 6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona sustituidos en 8.
ES2250721T3 (es) Derivados de 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona y 7-pirimidinil-2,3-dihidroimidazo(1,2-a)pirimidin-5(1h)ona sustituidos para enfermedades neurodegenerativas.
US8198287B2 (en) Substituted heteroaryl pyridopyrimidone derivatives
ES2328812T3 (es) Derivados de 8-perfluoroalquil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona sustituidos.
IL191213A (en) Transformed derivatives in the cycles of pyrimidone
CN101679364A (zh) 杂芳基酰胺嘧啶酮化合物
CN101679306B (zh) 治疗神经变性疾病的杂芳基酰胺取代的嘧啶酮衍生物
EP2148866B1 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
ES2250876T3 (es) Derivados de 1-(alquil), 1-(heteroaril)alquil y 1-((aril)alquil)-7-(pirimidin-4-il)-imidazo(1,2-a)pirimidin-5(1h)-ona.
ES2223008T3 (es) Compuestos utiles como ingrediente activo de un medicamento para el tratamiento preventivo y/o terapeutico de enfermedades neurodegenerativas.
CN100376576C (zh) 取代的2-(二氮杂-双环-烷基)-嘧啶酮衍生物
US7452897B2 (en) Use of substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1454908B1 (en) Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
EP1184385A1 (en) 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
HK1085742B (en) Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
HK1142074A (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases